Stray Dog

Names Anant Vinjamoori as chief medical officer

  • Good news: Dr Anant Vinjamoori becomes chief medical officer of the Hims brand, with a remit that includes longevity medicine and peptide therapies.
  • Good news: Peptides written into the official job description show they are part of formal company strategy, not just an investor narrative.
Read the full notes

HIMS has announced the appointment of Dr Anant Vinjamoori as chief medical officer of the Hims brand. He has a dual background in internal medicine and primary care and in longevity medicine, with more than 10 years of clinical and executive experience. He previously led the product and medical teams at Virta Health and Modern Age.

Read more

His remit covers sexual health, hormone health, dermatology, weight loss, mental health, longevity medicine and peptide therapies.

Investment thesis

Management is using this appointment to give substantive backing to the longevity-care platform narrative. Vinjamoori brings clinical skills in preventive medicine and product experience at health-tech companies, which fits HIMS's shift from telehealth towards preventive health management. Peptide therapies are written into the job responsibilities in the official press release, which shows peptides are now part of the company's formal strategic planning and not just an investor narrative.

Market data

Analyst coverage

15

Consensus target

28.7

100-day MA

23.76

20-day MA

25.36

50-day MA

24.59

Price

29.5

Price change (%)

7.8

Resistance

30.5

Weekly change (%)

5.0